## BMS-1001 hydrochloride

MedChemExpress

®

Cat. No.:	HY-120635	
CAS No.:	2113650-04-5	
Molecular Formula:	$C_{35}H_{35}CIN_2O_7$	HO_O HO
Molecular Weight:	631.11	
Target:	PD-1/PD-L1	
Pathway:	Immunology/Inflammation	H-CI
Storage:	4°C, sealed storage, away from moisture	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

## SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	1.5845 mL	7.9225 mL	15.8451 mL	
		5 mM	0.3169 mL	1.5845 mL	3.1690 mL	
		10 mM	0.1585 mL	0.7923 mL	1.5845 mL	
	Please refer to the so	lubility information to select the app	propriate solvent.			
In Vivo		1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.25 mg/mL (1.98 mM); Clear solution				
		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.25 mg/mL (1.98 mM); Clear solution				

BIOLOGICAL ACTIVITY		
Description	BMS-1001 is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 exhibits low-toxicity in cells. The IC <sub>50</sub> value of BMS-1001 in a homogeneous time-resolved fluorescence (HTRF) binding assay is 2.25 nM <sup>[1][2]</sup> .	
IC <sub>50</sub> & Target	PD-L1/PD-1 <sup>[1]</sup> .	
In Vitro	BMS-1001 binds to human PD-L1 and blocks its interaction with PD-1. BMS-1001 presents low toxicity towards tested cell lines and block the interaction of soluble PD-L1 with the cell surface-expressed PD-1. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

## REFERENCES

[1]. Guzik K, et al. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. J Med Chem. 2017 Jul 13;60(13):5857-5867.

[2]. Skalniak L, et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 2017 Aug 7;8(42):72167-72181.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA